Entelos Inc.



                                  Entelos, Inc.

                          ("Entelos" or "the Company")

The American Diabetes Association (ADA) and Entelos, Inc. (LSE: ENTL) announced
today extending its in silico (computer simulation) diabetes research center
capability and offering free access to Entelos' Realab(TM) "virtual mice"
testing platform to all ADA health professional members. Realab allows direct
web access to Entelos' state-of-the-art computer model of type 1 diabetes,
enabling scientists and clinicians an unparalleled ability to investigate the
onset, progression, and treatment of diabetes.

Using Realab, researchers can conduct simulations on drugs, drug combinations,
dose levels, dosing regimens, therapeutic targets, biological pathways and
functions on the primary animal model used to study type 1 diabetes. Realab's
virtual environments allow investigators to preview the likely effects of
different therapeutic interventions, helping to inform the optimal design of lab
experiments and clinical protocols.

The ADA and Entelos collaborated to develop the Type 1 Diabetes PhysioLab(R)
platform, a large scale computer-based mathematical model of the non-obese
diabetic (NOD) mouse, which is the simulation engine behind Realab for type 1
diabetes.

"There are now two ways that our members can benefit from Entelos' cutting-edge
simulation technology," said Richard Kahn, Ph.D., chief scientific and medical
officer, American Diabetes Association. "The first is through the diabetes
research center capability, which is available via a grant process. The second
is through direct online access of Entelos' Realab for type 1 diabetes research,
which we are now pleased to offer for free to all ADA health professional
members. We believe that this will not only accelerate adoption of this
innovative approach, it will also make a big impact on finding new therapies for
type 1 diabetes, which primarily affects children and young adults."

"One of the greatest disappointments for the pharmaceutical industry is having
experimental compounds that show early promise in animals that later fail
miserably when tested in humans," stated James Karis, president and CEO of
Entelos. "In building our initial model of a 'virtual mouse', scientific teams
at Entelos discovered subtle but important differences between species that can
have a big impact on interpreting results of animal studies and on designing
clinical trials. Our models and predictive platforms help to better translate
results and design experiments to make animal studies more meaningful and
relevant for finding effective medicines for patients. We plan to increase
access to Entelos' powerful simulation technology to enhance researchers'
capabilities to rapidly test 'virtual mice' and 'virtual patients' and
ultimately use fewer animals, run more decisive clinical trials, and save time
and money."

Realab currently has a virtual environment available for type 1 diabetes.
Environments for rheumatoid arthritis, cardiovascular disease and type 2
diabetes are under development by Entelos. Details regarding Realab can be found
at http://realab.entelos.com

For further information please contact:

Entelos, Inc.
James Karis, President and CEO                             Tel: +1 650 572 5400
Jill Fujisaki, VP Investor Relations
American Diabetes Association
Diane Tuncer                                       Tel: +1 703 549 1500, x 5510
Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson                      Tel +44 (0) 20 7466 5000

Notes to Editors

About Realab(TM)

Realab(TM) was developed by Entelos to provide scientists and clinicians with
personalized web-based access to Entelos' award-winning PhysioLab(R) technology
and computer models of human and animal disease physiology. Realab's virtual
environments allow investigators to preview the likely effects of different
therapeutic interventions in advance, helping to inform the optimal design of
research and clinical protocols in the real world.

The Realab web-based tool facilitates the design and submission of experiments
and clinical protocols. The investigator uses a menu system to select from
available predefined options for each simulation analysis including drugs, drug
combinations, dose levels, dosing regimens, therapeutic targets, biological
pathways, functions, patient or animal phenotypes and sampling intervals.

Once a Realab protocol is submitted, simulation results are available in Realab
within 24 hours for later analysis at the user's convenience. Researchers can
visualize the predicted outcome of the Realab protocol using graphs and other
tools to investigate the underlying biological mechanisms responsible for each
predicted outcome.

Realab currently has a virtual environment available for type 1 diabetes with
predefined experiments, about a dozen therapies and 75 possible model outputs.
Access to Realab simulations for non-ADA members can be purchased online or via
purchase order.

About the Type 1 Diabetes PhysioLab Platform

The Entelos(R) Type 1 Diabetes PhysioLab(R) platform is a large-scale,
mathematical model of the non-obese diabetic (NOD) mouse designed to support
research in type 1 diabetes. The platform captures the physiology of pancreatic
cell autoimmunity and tolerance from birth until disease onset. Virtual NOD mice
are constructed using equations that mathematically represent cellular functions
and biochemical interactions in tissues critical for the pathogenesis of type 1
diabetes. The model encompasses two main tissues: pancreatic lymph nodes (PLN)
and pancreatic islets. Antigen and antigen-presenting cells traffic from the
islets to the PLN, and conversely, lymphocytes activated in the PLN can enter
the blood and be recruited to the islets. Functions at the biochemical and
cellular levels are integrated and the dynamic relationships over time
quantitatively linked via mathematical equations, making simulation and
prediction of biological outcomes possible.

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual patients", and toxicology reference systems to
develop safer and more effective drugs and support pharmaceutical R&D and
commercialization. In addition to internal drug programs in rheumatoid arthritis
and women's health, Entelos provides customized technology and research services
to global pharmaceutical and health-care companies in cardiovascular diseases,
asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and
skin sensitization. The Company is also developing a model in oncology and is
collaborating with the FDA to build a model of drug-induced liver injury.
Entelos also offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys Ltd.

About the American Diabetes Association

The American Diabetes Association (www.diabetes.org) is the nation's premier
voluntary health organization supporting diabetes research, information and
advocacy. Founded in 1940, the Association has offices in every region of the
country, providing services to hundreds of communities. The Association's
commitment to research is reflected through its scientific meetings; education
and provider recognition programs; and its Research Foundation and Nationwide
Research Program, which fund breakthrough studies looking into the cure,
prevention, and treatment of diabetes and its complications. For more
information, please visit www.diabetes.org or call 1-800-DIABETES
(1-800-342-2383). Information from both these sources is available in English
and Spanish.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Entelos Regs Charts.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Entelos Regs Charts.